Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233812 | 0.89 | AVPR1A (0.46) | HPGDRAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3233628 | 0.86 | AVPR1A (0.43) | HPGDSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL3226477 | 0.85 | KMT2A (0.40) | HPGDSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL3230306 | 0.85 | HTT (0.43) | HPGDRAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3230218 | 0.84 | ALDH1A1 (0.40) | HPGDRAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3226270 | 0.83 | GNRHR (0.39) | HPGDSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL3235527 | 0.83 | GNRHR (0.39) | HPGDSMN1; SMN2LMNAALDH1A1KMT2A | |
| SCHEMBL3238705 | 0.83 | AVPR1A (0.44) | HPGDRAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3238699 | 0.83 | AVPR1A (0.44) | HPGDRAB9ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3235299 | 0.82 | AVPR1A (0.46) | LMNAALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097374-B1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI AVENTIS (FR) | 2010-06-09 | — | — | EP | claimed |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | claimed |
| EP-2097374-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | claimed |
| WO-2008087278-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | claimed |
| EP-2097374-B1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI AVENTIS (FR) | 2010-06-09 | — | — | EP | disclosed |
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| EP-2097374-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008087278-A2 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY AS SELECTIVE LIGANDS OF V2 VASOPRESSIN RECEPTORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069384-A1 | 5-ALKYLOXY-INDOLIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPY | AVPR2, AVPR1A, AVPR1B | HPGD 271/4885RAB9A 1844/4885SMN1; SMN2 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.